The future of the global stent market looks promising with opportunities in the hospital and ambulatory surgical center markets.
- Within the type category, coronary stents is expected to witness higher growth over the forecast period due to the rising prevalence of cardiovascular diseases globally.
- Within the end use category, hospital is expected to witness higher growth over the forecast period due to the increasing advanced cardiac treatment procedures demand.
- In terms of regions, APAC is expected to witness the highest growth over the forecast period due to the expanding healthcare infrastructure and rising patient base.
Emerging Trends in Stent Market
Between 2025 and 2027, the stent market moves from volume to evidence-based use. Drug-eluting stents will still dominate, but the market will broaden with the adoption of bioresorbable scaffolds, structural heart and other peripheral devices, and image-guided interventions. Lucintel expects the stent market will be affected by pricing pressure, clinical differentiation, and regional manufacturing.- Sustainability: The focus will continue to move away from 2015's supply-side cost reduction and toward 2015's demand-side cost shifts, which means suppliers will need to adapt. Enhanced waste management and continuous reduction of resource consumption in hospitals will drive changes in healthcare product procurement.
- Digital Manufacturing: The use of three-dimensional printing and other digital manufacturing and advanced imaging technologies to develop patient-specific devices will improve and create opportunities in the medical device market.
- Premiumization: The stent market will shift toward higher-value devices, especially where outcomes justify reimbursement and lower procedure costs. The global market for PCI is estimated to be over 4 million procedures annually.
- Automation: Although initially developed at a few centers, automated PCI and measurement of lesions are likely to expand. The number of robotic systems installed worldwide reached 1,000 by 2025. The use of robotics in PCI allows consistent placement of stents, and eliminates the variability of the operators. This development will improve access to PCI in remote and underserved locations.
- Regional Supply Chain Diversification: Disruptions in the global trade landscape and the increasing reliance on medical devices have accelerated local finishing and sourcing and diversification of regional supply. The strategy adopted by India’s 2025 medical devices policy to locally manufacture 70% to 80% of its medical devices will transform qualification and selection of vendors and manufacturing investments by 2030.
Recent Developments in the Stent Market
Cardiovascular disease (CVD) remains a burden around the world and the stent market is expected to grow as a result. For example, clinical evidence supports percutaneous coronary interventions (PCI) for acute myocardial infarction (AMI) treatment. Additionally, hospitals are seeking ways to control costs. Lucintel expects a positive outlook for the market. The company expects drug-eluting stents will maintain market dominance in the short-term. Innovation for other technologies is expected.- Peripheral Expansion: Boston Scientific’s acquisition of Cortex (Cortex is an atherectomy device company) in 2025 is expected to positively impact the consolidation of the peripheral device market. Other companies may follow and expand into other peripheral devices.
- Bioresorbable Innovations: Abbott’s Esprit bioresorbable scaffold is expected to obtain additional clinical evidence for the treatment of below-the-knee PAD. If evidence supports clinical application, other innovations may be adopted for treatment.
- Complex Lesion Platforms: Boston Scientific also predicted an enhanced drug-eluting stent to treat more complex forms of coronary disease. The stent is expected to increase the coverage area of coronary stents. If evidence supports the delivery of the stent, it may gain market share.
- Imaging Integration: In 2025, Philips expanded its partnerships to integrate 2025 intravascular imaging and catheter laboratory partnerships to support image-guided stent placement. This may allow interventional cardiologists to place stents in a more precise anatomical location and helps reduce geographic misses and repeat procedures, especially when imaging is used in conjunction with catheter-based guidance and information systems. This may lead to a stronger commercial case for stent and procedural bundle combinations.
- Regulatory Momentum: In 2025, the FDA granted numerous approvals for stent-related devices for both coronary and peripheral indications. This increases competition for a larger addressable market. With each approval, devices are required to demonstrate enhanced clinical evidence, increasing the cost of market entry for stent manufacturers. In addition, stronger clinical evidence allows stent manufacturers to better position their products for specific indications, including highly complex procedures.
Strategic Growth Opportunities in the Stent Market
From 2024-2026, stent market economics will likely shift away from unit growth to include differentiated coatings and clinical value. During the same time period, shifting demographics (i.e. aging and larger populations, prevalence of diabetes, reimbursement, outpatient surgery), will broaden the market. Lucintel’s Market Perspective pointed to fragmentation as hospital administrators will become increasingly more focused on quantifiable outcomes.- Complex-lesion Devices: Bifurcation and chronic total occlusion stenting are likely to increase as the median patient age rises. A March 2025 multicenter study reported 92% procedural success with a stent in the treatment of complex lesions.
- Drug-eluting Devices: Clinical studies will focus on next-generation drug-eluting stents, particularly those with improved biocompatibility, to show a reduction in restenosis. A shorter hospital stay would result in significant cost savings.
- Peripheral Vascular Devices: Diabetes-associated peripheral vascular disease remains significantly underdiagnosed and untreated, leaving an opportunity for dedicated below-the-knee and femoropopliteal stent devices. A June 2025 regional screening program showed peripheral vascular disease in 27% of a high-risk population. Ongoing educational efforts are likely to create a larger opportunity in the same time frame.
- New Markets: Stent adoption is likely to increase throughout India, Southeast Asia, Latin America, and selected sub-Saharan markets due to local manufacturing and joint distributorship. February 2025, the Indian Government’s National Health program extended coverage to over 1.4 billion residents.
- Post-procedure Monitoring: Connected follow-up tools integrated with imaging and patient records can create recurring service revenue streams and potentially assist in identifying restenosis earlier. In August 2025, a hospital network reported remote follow-up for 18,000 cardiovascular patients. In the future, monitoring will be a key differentiator as providers demand evidence beyond implantation.
Stent Market Drivers and Challenges
Growing technology, cardiovascular disease, and healthcare investment will foster growth in the stent market. Rising demand for safer and less invasive therapies creates growth potential, but so do pricing and evidence challenges. Lucintel identifies innovation, manufacturing, and distribution as key elements that will impact the market.The factors responsible for driving this market include:
- Innovation: The development of new drugs and drug-eluting platforms are improving outcomes by lowering restenosis and enabling more personalized interventions. Clinical trials continued to assess the safety and efficacy of next-generation drug-eluting stents with thinner struts and improved deliverability in January 2025. In the next three to five years, improved safety and flexibility will encourage interventionists to expand the indications for coronary stents for the treatment of more complex lesions, and to replace older devices for use in more complex peripheral interventions.
- Improving Technology: The field of interventional cardiology is progressing with the integration of imaging, robotics, and artificial intelligence. March 2025, hospital programs involving the use of technology-assisted cardiovascular programs reported continued adoption of intravascular imaging to assess lesions. The integration of these technologies will impact the market by reducing the uncertainty of procedural outcomes and, ultimately, improve health outcomes by reducing the need for permanent procedures.
- Regulatory Support: The availability of stent technologies can be improved with the help of pathways for breakthrough devices, evidence-based clinical guidance and quality standards. In April 2025, regulators continued to encourage the use of evidence-based pathways for the evaluation of cardiovascular devices, including long-term safety. More relevant requirements and guidance in the next three to five years will help develop confidence among physicians and patients and lead to improved acceptance of medical devices.
- Manufacturing Improvements: Digital technologies and automation allow manufacturers to reduce costs and improve the consistency of medical devices. In June 2025, a focus among medical device manufacturers was on automated systems for micron-level tolerance inspection, coating and packaging. Continuous improvements in automation and digital technologies will help reduce the cost of medical devices and encourage competition in the marketplace.
The challenges facing this market include:
Costs of Procedures: Stent procedures are expensive: involving costs for the device, hospitalization, imaging, and professional fees for specialization and follow-up. Cost barriers can limit access to the procedures in regions without adequate reimbursement. In May 2025, several healthcare systems continued reviewing their cardiovascular budgets, leading to the cancellation of some high-cost, low-impact procedures. In developing markets, costs will remain a barrier for accessing stent procedures in the next three to five years unless there is greater local production of stents and associated equipment, and reforms to reimbursement and value-based purchasing.- Clinical and Regulatory Complexity: The testing required to demonstrate the safety and effectiveness of stents is extensive and includes evaluations of biocompatibility, durability, thrombosis, and long-term patient outcomes. In August 2025, regulatory authorities continued to require post-market surveillance and comparative data for novel cardiovascular devices. The above will prolong the time to market, increase R&D expenditures, and favor companies with strong clinical and regulatory experience. It may also delay the time to market for more innovative products from smaller companies.
- Complications and Reimbursement Pressure: Restenosis, thrombosis, bleeding, vascular injury, and the need for repeat procedures impact clinical confidence and increase the cost of care. In October 2025, hospitals continued to prioritize outcome-based procurement and monitored cardiovascular readmission rates. In the next 3 to 5 years, there will be pressure on device companies to demonstrate durable benefits. Simultaneously, reimbursement may add further pressure on companies to compete on price and shift the focus of clinical practice to the use of stents with clear clinical and economic benefits.
List of Stent Market Companies
Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. Through these strategies stent market companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base.Some of the stent market companies profiled in this report include:
- Abbott Laboratories
- Boston Scientific
- Medtronic Public Limited Company
- C.R. Bard
- Cook Medical Inc.
- Terumo Corporation
- Cardinal Health
Stent Market by Segment
The study includes a forecast for the global stent market by type, material, technology, end use, and region.Type [Value ($M) from 2019 to 2035]:
- Coronary Stents
- Peripheral Vascular Stents
Material [Value ($M) from 2019 to 2035]:
- Metal
- Polymer
Technology [Value ($M) from 2019 to 2035]:
- Bare Metal Stents
- Drug Eluting Stents
- Bioreabsorbable Stents
End Use [Value ($M) from 2019 to 2035]:
- Hospital
- Ambulatory Surgical Center
Region [Value ($M) from 2019 to 2035]:
- North America
- Europe
- Asia Pacific
- The Rest of the World
Country Wise Outlook for the Stent Market
Rapid changes in the stent market include localized manufacturing, consolidation in the healthcare sector, and regular approvals by regulatory agencies. Leading companies are focusing on different platforms such as drug-eluting stents, bioresorbable stents, and stents for the structural heart between 2025 and 2027. According to Lucintel’s newest market analysis, these trends have increased competition in key markets.- United States: Boston Scientific expanded its portfolio through the acquisition of Cortex in January 2025, broadening its offerings for complex coronary interventions, and putting pressure on Abbott’s bioresorbable scaffold, Esprit, which is still in clinical and commercial development in the U.S. The above-mentioned trends will create additional minimally invasive treatment options and reinforce domestic supplier scope in the U.S. in the next 3-5 years.
- China: The National Healthcare Security Administration continued centralized, volume-based procurement of coronary stents in 2020 and lowered average prices by about 93%. Domestic manufacturers have recently launched locally made drug eluting stents, and peripheral stents. This will result in greater cost based competition, and improve hospital’s access to cardiac stents in China.
- Germany: Continuing implementation of the EU Medical Device Regulation by 2025, aligned with stricter certification standards will create an environment that favors well-capitalized companies with validated production and documentation systems. Siemens Healthineers, reported €22.4 billion revenue for fiscal year 2024 (November 2024).
- India: Production Linked Incentive (PLI) scheme (2025) supports local medical device manufacturing. Meril Life Sciences, a domestic medical device manufacturer, expanded its cardiovascular device manufacturing facilities in Gujarat. The above will strengthen local manufacturing of cardiovascular devices. Public hospitals can also enjoy affordable medical devices, manufactured locally.
- Japan: In April 2025, the Ministry of Health, Labour and Welfare, implemented the reimbursement revision for fiscal year 2025, which included cardiovascular devices. Other developments include Terumo’s continued marketing of its coronary and peripheral intervention devices. These changes will focus on the need for evidence to aid reimbursement and clinical acceptance of cardiovascular devices in the Japanese market.
Features of the Global Stent Market
- Market Size Estimates: stent market size estimation in terms of value ($M).
- Trend and Forecast Analysis: Market trends (2019 to 2026) and forecast (2027 to 2035) by various segments and regions.
- Segmentation Analysis: stent market size by various segments, such as by type, material, technology, end use, and region in terms of value ($M).
- Regional Analysis: stent market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
- Growth Opportunities: Analysis of growth opportunities in different type, material, technology, end use, and regions for the stent market.
- Strategic Analysis: This includes M&A, new product development, and competitive landscape of the stent market.- Analysis of competitive intensity of the industry based on Porter’s Five Forces model.
This report answers the following 11 key questions:
Q.1. What are some of the most promising, high-growth opportunities for the stent market by type (coronary stents and peripheral vascular stents), material (metal and polymer), technology (bare metal stents, drug eluting stents, and bioreabsorbable stents), end use (hospital and ambulatory surgical center), and region (North America, Europe, Asia Pacific, and the Rest of the World)?Q.2. Which segments will grow at a faster pace and why?
Q.3. Which region will grow at a faster pace and why?
Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
Q.5. What are the business risks and competitive threats in this market?
Q.6. What are the emerging trends in this market and the reasons behind them?
Q.7. What are some of the changing demands of customers in the market?
Q.8. What are the new developments in the market? Which companies are leading these developments?
Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?
This product will be delivered within 1-3 business days.
Table of Contents
Companies Mentioned
- Abbott Laboratories
- Boston Scientific
- Medtronic Public Limited Company
- C.R. Bard
- Cook Medical Inc.
- Terumo Corporation
- Cardinal Health
Methodology
The analyst has been in the business of market research and management consulting since 2000 and has published over 600 market intelligence reports in various markets/applications and served over 1,000 clients worldwide. Each study is a culmination of four months of full-time effort performed by the analyst team. The analysts used the following sources for the creation and completion of this valuable report:
- In-depth interviews of the major players in the market
- Detailed secondary research from competitors’ financial statements and published data
- Extensive searches of published works, market, and database information pertaining to industry news, company press releases, and customer intentions
- A compilation of the experiences, judgments, and insights of professionals, who have analyzed and tracked the market over the years.
Extensive research and interviews are conducted in the supply chain of the market to estimate market share, market size, trends, drivers, challenges and forecasts.
Thus, the analyst compiles vast amounts of data from numerous sources, validates the integrity of that data, and performs a comprehensive analysis. The analyst then organizes the data, its findings, and insights into a concise report designed to support the strategic decision-making process.

LOADING...

